Tetherin-Driven Adaptation of Vpu and Nef Function and the Evolution of Pandemic and Nonpandemic HIV-1 Strains by Sauter, Daniel et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tetherin-Driven Adaptation of Vpu and Nef Function and the
Evolution of Pandemic and Nonpandemic HIV-1 Strains
Citation for published version:
Sauter, D, Schindler, M, Specht, A, Landford, WN, Muench, J, Kim, K-A, Votteler, J, Schubert, U, Bibollet-
Ruche, F, Keele, BF, Takehisa, J, Ogando, Y, Ochsenbauer, C, Kappes, JC, Ayouba, A, Peeters, M, Learn,
GH, Shaw, G, Sharp, PM, Bieniasz, P, Hahn, BH, Hatziioannou, T & Kirchhoff, F 2009, 'Tetherin-Driven
Adaptation of Vpu and Nef Function and the Evolution of Pandemic and Nonpandemic HIV-1 Strains' Cell
Host and Microbe, vol 6, no. 5, pp. 409-421. DOI: 10.1016/j.chom.2009.10.004
Digital Object Identifier (DOI):
10.1016/j.chom.2009.10.004
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Cell Host and Microbe
Publisher Rights Statement:
Free in PMC.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
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SUMMARY
Vpu proteins of pandemic HIV-1 M strains degrade the viral receptor CD4 and antagonize human
tetherin to promote viral release and replication. We find that Vpus from SIVgsn, SIVmus and
SIVmon infecting Cercopithecus primate species also degrade CD4 and antagonize tetherin. In
contrast, SIVcpz, the immediate precursor of HIV-1, whose Vpu shares a common ancestry with
SIVgsn/mus/mon Vpu, uses Nef rather than Vpu to counteract chimpanzee tetherin. Human tetherin,
however, is resistant to Nef and thus poses a significant barrier to zoonotic transmission of SIVcpz
to humans. Remarkably, Vpu from non-pandemic HIV-1 O strains are poor tetherin antagonists while
those from the rare group N viruses do not degrade CD4. Thus, only HIV-1 M evolved a fully
functional Vpu following the three independent cross-species transmissions that resulted in HIV-1
groups M, N, and O. This may explain why group M viruses are almost entirely responsible for the
gobal HIV/AIDS pandemic.
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INTRODUCTION
Primate lentiviruses such as HIV and SIV encode several accessory proteins. These include
Vif, Vpr, Vpu, Vpx, and Nef, and are usually dispensable for viral growth in vitro. However,
they are important for viral replication in vivo because they counteract host restriction factors,
enhance viral replication and virion infectivity, or facilitate viral evasion of the adaptive
immune response (reviewed in Malim and Emerman, 2008). Vif, vpr and nef are found in the
genomes of all primate lentiviruses. In contrast, vpu genes were initially only found in HIV-1
and its precursor SIVcpz from chimpanzees (Pan troglodytes), but not in HIV-2 or other SIV
strains (Cohen et al., 1988; Huet et al., 1990; Gao et al., 1999; Santiago et al., 2003).
Subsequently, molecular characterization of SIVs from additional primate species revealed
that the genomes of SIVgsn, SIVmon, SIVden and SIVmus from greater spot-nosed
(Cercopithecus nictitans), mona (C. mona), Dent's mona (C. denti) and Mustached monkeys
(C. cephus), as well as SIVgor from gorillas (Gorilla gorilla gorilla) also carry vpu genes
(Barlow et al., 2003; Courgnaud et al., 2002; Courgnaud et al., 2003; Dazza et al., 2005;
Takehisha et al., 2009). SIVcpz, which gave rise to pandemic (M, main) and non-pandemic
(O, outlier and N, non-M, non-O) groups of HIV-1 and also to SIVgor (which is closely related
to HIV-1 O; Van Heuverswyn et al., 2006), is the product of successive cross-species
transmission and recombination events involving precursors of today’s SIVgsn/mus/mon/den
and SIVrcm from red-capped mangabeys (Cercocebus torquatus) (Bailes et al., 2002). Thus,
all vpu genes likely originated from a common ancestor of the SIVgsn/mus/mon/den lineage
of primate lentiviruses (Kirchhoff, 2009).
Vpu is an ~80 amino acid integral class I membrane phosphoprotein (Cohen et al., 1988;
Maldarelli et al., 1993). Studies performed with HIV-1 NL4-3 Vpu have established two main
functions. First, Vpu induces the degradation of the primary viral receptor CD4 by a multi-step
process that involves direct binding of Vpu to the cytoplasmic tail of CD4 in the endoplasmic
reticulum (Bour et al., 1995, Margottin et al., 1998; Willey et al., 1992). Second, Vpu promotes
the release of progeny virions from HIV-1-infected human cells (Strebel et al., 1988; Klimkait
et al., 1990; Gottlinger et al., 1993) by antagonizing a recently identified restriction factor,
termed tetherin (also known as CD317, BST2 or HM1.24), that is induced by interferon-alpha
and results in the ‘tethering’ of nascent virions to the cellular plasma membrane (Neil et al.,
2008; Van Damme et al., 2008). Tetherin has a broad antiviral activity and inhibits the release
of various enveloped viruses (Jouvenet et al., 2009; Kaletsky et al., 2009; Sakuma et al.,
2009). Furthermore, monkey and rodent tetherins block virion release but are not counteracted
by HIV-1 Vpu (Goffinet et al., 2009; Gupta et al., 2009; McNatt et al., 2009; Wong et al.,
2009).
To date, functional data have almost exclusively been derived from the Vpu protein of the T-
cell line adapted HIV-1 NL4-3 molecular clone. It is thus unknown to what extent CD4
degradation and tetherin antagonism are conserved among the diverse Vpu proteins found in
HIV-1 and SIVs and how Vpu function evolved following zoonotic transmissions of primate
lentiviruses from monkeys to chimpanzees and, ultimately, to humans. To address these
questions, we analyzed a panel of vpu constructs representing nearly the entire spectrum of
primate lentiviruses known to encode this accessory gene, i.e. HIV-1 M, O and N, SIVcpz,
SIVgor, SIVgsn, SIVmon and SIVmus. We show that all Vpu proteins, except those found in
HIV-1 group N, degrade human CD4, whereas tetherin is antagonized in a more species-
specific manner. Unexpectedly, we found that SIVcpz employs Nef rather than Vpu as a
tetherin antagonist. Following transmission of SIVcpz to humans, HIV-1 group M Vpu and
not Nef acquired an anti-tetherin activity in addition to its abilty to degrade CD4, most likely
because the human tetherin has a deletion in its cytoplasmic domain that disrupts its
susceptibility to Nef (Zhang et al., 2009). In contrast, Vpus of non-pandemic HIV-1 group O
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and N strains that resulted from independent zoonotic transmissions (Hahn et al., 2000; Van
Heuverswyn and Peeters, 2007) either do not antagonize human tetherin (group O strains) or
are unable to degrade CD4 (group N strains). Thus, the evolution of a fully functional Vpu
protein may have been an important prerequisite for the efficient spread of HIV-1 group M in
the human population.
RESULTS
Primate Lentiviral Vpus are Highly Variable but Exhibit some Conserved Features
To examine to what extent CD4 degradation and anti-tetherin activity are conserved among
primate lentiviral Vpus, we analyzed a large panel of HIV-1 and SIV vpu alleles (Table S1).
Our collection included Vpu constructs from 26 strains of HIV-1 group M, 11 strains of HIV-1
O, three strains of HIV-1 N, six strains of SIVcpzPtt from central chimpanzees (CPZ), four
strains of SIVcpzPts from eastern chimpanzees, one strain of SIVgor from a Western lowland
gorilla (GOR), two strains of SIVgsn from greater spot-nosed monkeys (GSN), one strain of
SIVmon from a mona monkey (MON), and three strains of SIVmus from mustached monkeys
(MUS). The HIV-1 group M Vpus included all nine subtypes, as well as ten vpu alleles (8 clade
B and 2 clade C) from full-length infectious molecular clones of transmitted/founder viruses
obtained by single genome amplification of plasma virion RNA (Salazar-Gonzales et al., 2009).
Notably, all but two SIV vpu genes were amplified directly from the blood or fecal material of
naturally infected monkeys or apes (Table S1).
An amino acid alignment of representative primate lentiviral Vpus shows that they are highly
variable. Nonetheless, some features, including a hydrophobic N-terminal membrane anchor
domain, a putative central α-helical region with hydrophobic, basic and acidic residues and an
acidic C-proximal region, are usually conserved (Figure 1). Two serine residues (S52 and S56),
known to be phosphorylated by casein kinase II and required for CD4 degradation by NL4-3
Vpu (Schubert and Strebel, 1994;Paul and Jabbar, 1997), were present in all HIV-1 and
SIVcpzPtt Vpus. In the remaining Vpus, the number and location of serine residues varied,
although at least one potential serine phosphorylation site was always preserved (Figure 1).
Thus, despite their exceedingly high variability, primate lentiviral Vpus exhibit common
sequence signatures.
All Vpu proteins - except those from HIV-1 group N - induce CD4 degradation
To determine which primate lentiviral Vpus prevent cell surface expression of CD4, we
cotransfected 293T cells with vectors coexpressing Vpu and GFP (or GFP alone for control)
together with a human (HU) CD4 expression construct. In the absence of Vpu, cells expressed
high levels of CD4 and GFP (Figure 2A). However, upon coexpression of most Vpus, CD4
surface expression was markedly decreased (examples are shown in Figure 2A). This effect
was Vpu specific since it was abrogated by a single S52A mutation in the cytosolic domain of
the HIV-1 NL4-3 Vpu, previously shown to be critical for CD4 degradation (Schubert and
Strebel, 1994; Paul and Jabbar, 1997). Quantitative analysis of CD4 surface levels (Fig. 2B)
showed that most SIVgsn, SIVmon, SIVmus, SIVcpz and SIVgor, as well as HIV-1 M and O
Vpus reduced CD4 cell surface expression by more than 80% (Figure 2B). In striking contrast,
each of three HIV-1 group N Vpu proteins lacked this function (Figure 2B). These functional
differences were statistically highly significant (p<0.0001). Analysis of Vpus containing a C-
terminal AU-1-tag confirmed these results and showed that all but one construct expressed
proteins of the expected size (Figure S1 and data not shown). These results show that the ability
of blocking CD4 cell surface expression is highly conserved among primate lentiviral Vpus -
with the notable exception of HIV-1 N Vpu, which lacks this function (Figure 2B).
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SIVcpz, SIVgor and HIV-1 group O Vpus do not Efficiently Antagonize Tetherin
It has recently been shown that the HIV-1 NL4-3 Vpu antagonizes tetherin in a species-specific
manner, i.e. it exhibited activity against human but not monkey (i.e. rhesus macaque, RM and
African green monkey, AGM) or rodent tetherins (Goffinet et al., 2009; Gupta et al., 2009;
McNatt et al., 2009). To determine the anti-tetherin activity of other primate lentiviral Vpus
we generated vectors that expressed GSN, MON, MUS, CPZ, GOR, HU, AGM and RM
tetherin molecules (Table S2). As shown in Figure 3A, the sequence of the transmembrane
(TM) domain of tetherin, which has been evolving under positive selection and determines its
susceptibility to HIV-1 NL4-3 Vpu (McNatt et al., 2009; Gupta et al., 2009), varies
substantially between higher primates and monkeys, but is conserved between humans, gorillas
and chimpanzees (except for a V35M variation between HU and CPZ tetherins; Figure 3A).
In comparison, the TM domains of the six monkey tetherin sequences differed at a total of four
amino acid positions. All tetherin proteins were expressed and suppressed HIV-1 release in the
absence of Vpu (Figure S2).
To test whether the various HIV-1 and SIV Vpus are capable of counteracting tetherins from
their respective hosts, as well as those from other species, we measured infectious virus yields
from 293T cells following cotransfection of a vpu-deleted (ΔVpu) HIV-1 proviral construct
(Rucker et al., 2004) with Vpu and tetherin expression plasmids. Our data showed that only
HIV-1 Vpus were effective antagonists of HU, CPZ and GOR tetherins (Figure 3B). In
comparison, SIVgsn, SIVmon and SIVmus Vpus counteracted the tetherins of their respective
host, as well as other monkey species (Figure 3B). The exception was SIVmon CML1 Vpu,
which was inactive against the MUS tetherin, which differs from the other monkey tetherins
by a L36F substitution and a single amino acid deletion (ΔL42) in the TM domain (Figure 3A,
B). Thus, HIV-1 group M Vpus potently antagonized tetherins of apes and humans but were
less effective against the monkey restriction factors, whereas SIVgsn, SIVmon and SIVmus
Vpus showed the opposite phenotype. Interestingly, the HIV-1 JR-CSF and YU-2 Vpus
exhibited some activity against GSN and AGM tetherins (Figure 3B), indicating that certain
HIV-1 Vpus have a broader anti-tetherin activity than the NL4-3 Vpu (Goffinet et al., 2009;
Gupta et al., 2009; Jia et al., 2009; McNatt et al., 2009). In agreement with previous studies
(McNatt et al., 2009), an exchange of the TM domain in HU tetherin with that of AGM or RM
rendered it resistant to HIV-1 Vpus but conferred sensitivity to SIVmon and SIVmus Vpus
(Figure S3).
While the functional profiles of HIV-1, SIVgsn, SIVmon and SIVmus Vpus were as expected,
the observed anti tetherin activities of ape virus Vpus came as a surprise: all SIVcpz Vpus,
including those derived from the closest relatives of the HIV-1 group M (i.e. LB7, MB897,
MB66) (Keele et al., 2006), failed to antagonize all eight different tetherins including that
derived from their cognate CPZ host (Figure 3B). Similarly, the Vpu protein of SIVgor had
only poor anti-tetherin activity. These results were confirmed by expressing the various Vpu
proteins in cis in the context of infectious HIV-1 molecular clones, using both tetherin
transfected 239T cells as well as HeLa cells expressing endogenous tetherin (see Supplemental
Results and Figure S4, Figure S5 and Figure S6). To control for intracellular viral gene
expression, we also examined the anti-tetherin activity of primate lentiviral Vpus by Western
blot analysis. The results confirmed that HIV-1 Vpus efficiently counteracted HU and CPZ
tetherins, but were less effective against those of AGM or RM, whereas Vpu proteins from
SIVgsn and SIVmus showed the opposite phenotype. They also confirmed that SIVcpz Vpus
lack significant anti-tetherin activity (Figure S7). Importantly, the Western blots also
demonstrated that the various Vpus acted specifically at the level of virion release into the
culture supernatants, and did not influence cell-associated levels of p24 antigen expression.
Our finding that SIVcpz Vpus are very poor tetherin antagonists suggested that HIV-1 group
M Vpus gained anti-tetherin activity during adaptation to the new human host. Thus, we next
Sauter et al. Page 4
Cell Host Microbe. Author manuscript; available in PMC 2010 November 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
examined whether Vpus from non-pandemic HIV-1 groups O and N strains (which represent
independent cross-species transmissions; Hahn et al., 2000; Van Heuverswyn and Peeters,
2007) also evolved the capability of antagonizing HU tetherin. Strikingly, we found that
(similarly to SIVcpz and SIVgor Vpus) HIV-1 group O Vpus generally displayed little if any
activity against the human tetherin (Figure 3C). In contrast, one HIV-1 group N Vpu (YBF30)
efficiently counteracted HU tetherin, while two others had more modest effects (Figure 3C).
These results were confirmed at various levels of HU tetherin expression (Figure S8). Thus,
only HIV-1 group M and N, but not HIV-1 group O Vpus, have acquired significant anti-
tetherin activity during viral adaptation to the human host.
Nef proteins from SIVcpz and SIVgor, but not from HIV-1 group O, antagonize Tetherin
Recently, it has been shown that the Nef proteins of some SIVs that lack a vpu gene (i.e. those
of SIVsmm/mac, SIVagm and SIVblu) counteract tetherin (Jia et al., 2009; Zhang et al.,
2009). We therefore examined whether SIVcpz, SIVgor and HIV-1 group O employ Nef rather
than Vpu to antagonize this restriction factor. Since primate lentiviral Nef proteins enhance
virion infectivity (Münch et al., 2007), it was expected that expression of Nef would enhance
the infectious virus yield but not p24 antigen release in the absence of tetherin (examples shown
in Figure S9). To account for this confounding variable, we normalized all infectious virus
yields to that obtained in the presence of Nef but the absence of tetherin (100%). After this
adjustment the relative levels of virus release measured by infectivity assays and by p24 antigen
ELISA correlated extremely well (R2 =0.93; Figure S9). We also measured the levels of cell-
associated p24 expression by ELISA and Western blot and found that neither Nef nor tetherin
affected these values.
First, we examined whether HIV-1, SIVcpz and SIVgor Nefs (Table S3) antagonize tetherin
from apes and humans by cotransfecting 293T cells with an HIV-1 proviral construct lacking
vpu and nef, tetherin expression vectors and constructs expressing various Nef proteins. The
results demonstrated that SIVcpz and SIVgor Nefs antagonize the tetherin molecules from their
cognate hosts but not the tetherin variant found in humans (Figure 4A). Insertion of five amino
acids (DDIWK) that are missing in the cytoplasmic domain of HU tetherin (Figure 3A) and
are known to confer sensitivity to SIVmac and SIVagm Nef (Jia et al., 2009; Zhang et al.,
2009) fully restored its susceptibility to SIVcpz and SIVgor Nef antagonism (HU-INS, Figure
4A). The disruptive effect of the N-terminal deletion in HU tetherin was highly significant
(p<0.0001). Some HIV-1 Nefs displayed modest activities against the CPZ, GOR and HU-INS
tetherins, but did not antagonize HU tetherin. The SIVgor Nef was more effective against the
GOR tetherin than any of six SIVcpz Nefs. Notably, the GOR and CPZ tetherin proteins differ
at only two amino acid positions in the cytoplasmic domain (D15A, W17L) at the same location
that governs sensitivity to other Nef proteins (Figure 4A). This strongly suggests that SIVgor
Nef has specifically adapted to antagonize tetherin in gorillas. To confirm these findings we
generated vpu-defective mutants of replication-competent HIV-1 NL4-3 proviral constructs
that coexpress GFP and different HIV-1 and SIVcpz nef alleles from bicistronic RNAs
(Schindler et al., 2006) and analyzed viral protein expression and release using Western blot
analyses. Our data confirmed that all SIVcpz Nefs antagonize CPZ (but not HU) tetherin
(Figure 4B). Notably, Nef proteins from other SIVs that encode Vpu proteins, i.e. SIVgsn,
SIVmon and SIVmus, did usually not counteract tetherins from their respective hosts (Figure
4C). In agreement with published data (Jia et al., 2009; Zhang et al., 2009), we found that the
nef alleles from SIVmac and SIVagm antagonize RM and AGM tetherins, albeit less efficiently
than SIVcpz Nefs (Figure 4C, and data not shown).
To detect possible weak anti-tetherin activities, we next compared the effects of various primate
lentiviral vpu and nef alleles on virus release at different doses of plasmids expressing the
tetherins from their respective hosts. These titration experiments confirmed that SIVgsn,
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SIVmus and SIVmon use mainly Vpu to antagonize tetherin (Figure 5A). The exception was
SIVgsn116 Nef which also displayed significant anti-tetherin activity, suggesting that this
primate lentivirus may use both accessory proteins to counteract this restriction factor. The
titration analyses also confirmed that SIVcpz and SIVgor use Nef and HIV-1 groups M and N
use Vpu to antagonize tetherin (Figure 5A, B). We also assessed whether HIV-1 O Nefs
counteract HU tetherin at lower concentrations, since a weak enhancement of infectious virus
release in the presence of HU tetherin was observed in some experiments (Figure 5B). These
titration analyses showed that HIV-1 group O Nefs are just as inactive against HU tetherin as
those of SIVcpz (Figure 5C). Moreover, HIV-1 group O Nefs were less potent antagonists of
CPZ tetherin than SIVcpz Nefs (Figure 4A, Figure 5C). Thus, HIV-1 group O strains appear
to have lost some of their Nef-associated anti-CPZ-tetherin activity following transmission to
humans. Taken together, our results demonstrate that SIVcpz and SIVgor (but not HIV-1
groups M, N and O) use Nef rather than Vpu to antagonize tetherin.
DISCUSSION
CD4 Degradation and Tetherin Antagonism are Conserved Among Primate Lentiviruses
In this study, we examined the evolution of Vpu function in the primate lentiviruses whose
ancestors gave rise to HIV-1. We show that the two major functions of the HIV-1 NL4-3 Vpu
protein, i.e. CD4 degradation and enhancement of virion release by counteracting tetherin, are
conserved in other vpu-containing non-human primate lentiviruses (summarized in Figure 6A).
Nonetheless, important differences were noted. First, Vpu appears to require some host-
specific adaptation in order to be an effective tetherin antagonist since Vpus from SIVgsn,
SIVmus and SIVmon were only active against monkey tetherins and those from HIV-1 group
M were only effective against ape and human tetherins (Figure 3B). In comparison, host-
specific adaptation seems less important for CD4 downmodulation since the great majority of
primate lentiviral Vpu and Nef proteins is active against human CD4 (Figure 2; Schindler et
al., 2006). Second, we found that SIVcpz employs Nef rather than Vpu to antagonize tetherin
(Figure 3C and 4C). This finding was unexpected given that the vpu genes of SIVcpz, SIVgsn,
SIVmus and SIVmon share a common ancestor (Schindler et al., 2006) and because previous
studies suggested that only SIVs that do not contain a vpu gene use Nef to antagonize tetherin
(Jia et al., 2009; Zhang et al., 2009). Third, we found that SIV Nefs generally fail to counteract
HU tetherin because a deletion in the TM domain of the human restriction factor disrupts its
susceptibility to Nef (Figure 4A) (Jia et al., 2009; Zhang et al., 2009). Together, these findings
suggest that tetherin poses a significant - albeit not insurmountable - barrier to transmission of
non-human primate lentiviruses to humans. Moreover, it seems that only the pandemic HIV-1
M group has entirely cleared this hurdle because its Vpu protein evolved to become an effective
tetherin antagonist, yet maintained its ability to degrade CD4. We therefore speculate that the
acquisition of a fully functional Vpu protein by the main group of HIV-1 contributed to the
global spread of the AIDS pandemic.
Switching between Nef- and Vpu-mediated antagonism of Tetherin may have Facilitated
Primate Lentiviral Zoonoses
It may seem surprising that SIVcpz uses Nef to antagonize tetherin but switched to use Vpu
following transmission to humans. Although further studies are necessary to fully elucidate
the evolution of Vpu and Nef functions, a possible scenario is outlined in Figure 6. Recent data
show that some primate lentiviruses that do not encode a vpu gene use Nef to antagonize tetherin
(Jia et al., 2009; Zhang et al., 2009). Our observation that Vpus from SIVgsn, SIVmus and
SIVmon are all capable of counteracting their cognate tetherin suggests that this function was
already present in the vpu-containing common ancestor of these viruses (Figure 6B, upper left).
Evolutionary analyses indicate that SIVcpz received vpu from the precursor of the SIVgsn/
mus/mon lineage, while its nef gene is derived from the SIVrcm lineage (Bailes et al.,
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2003;Schindler et al., 2006). Thus, during the adaptation of SIVcpz to its chimpanzee host,
either Nef or Vpu could have served as the tetherin antagonist. Because both Nef and Vpu
antagonize tetherin in a host-specific manner, it is likely that initially they were both only
poorly active against the CPZ tetherin (Figure 6B, middle). Our data show that Nef
subsequently evolved to become an effective antagonist of CPZ tetherin, possibly because the
cytoplasmic tail (CT) of the chimpanzee tetherin differs less from that of monkey tetherins
than the TM domain which governs susceptibility to Vpu (Figure 3A). Furthermore, the
recombinant virus that comprises SIVcpz (Bailes et al., 2003) may have had a selective
advantage over its non-mosaic precursors because its Vpu was capable of degrading CD4 while
its Nef was capable of exerting an anti-tetherin activity. Upon cross-species transmission of
SIVcpz to humans, however, the Nef-mediated tetherin antagonism was lost, most likely
because a deletion in the cytoplasmic domain of the human tetherin abrogated its sensitivity
to Nef. This deletion, which may have evolved in humans following encounters with other
pathogens, made it difficult, if not impossible, for Nef to restore its anti-tetherin function.
Hence, none of the 14 HIV-1 group M, N and O Nefs that we tested had an appreciable activity
against HU tetherin. In contrast, the SIVgor Nef was able to adapt to antagonize the GOR
tetherin, most likely because that restriction factor differs from that of CPZ only by two amino
acid substitutions in the CT domain. Consistent with this hypothesis are recent findings
showing that SIVsmm and SIVmac Nefs are antagonists of monkey but not human tetherin
(Jia et al., 2009; Zhang et al., 2009). Furthermore, HIV-2, which originated from SIVsmm,
appears to use Env to facilitate the release of progeny virions from human cells (Bour and
Strebel, 1996), although it remains to be elucidated whether this effect is due to Env-mediated
tetherin antagonism. Our data show that the HIV-1 group M Vpu evolved to become an
effective antagonist of HU tetherin (Figure 6B, upper right). Thus, the flexibility to switch
between Nef and Vpu (which is lacking in HIV-2) to counteract tetherin may have facilitated
two cross-species transmission events which may otherwise have been less successful: (i) the
transmission of SIVgsn/mus/mon to chimpanzees and (ii) the transmission of SIVcpz to
humans (Figure 6).
Multi-functionality of Accessory Proteins May Increase the Potential for Cross-Species
Transmission of Primate Lentiviruses
In contrast to their effect on tetherin, the ability of SIV Vpus to degrade CD4 has been well
preserved, and this is also true for most SIV Nef proteins (Schindler et al., 2006). Thus, at least
two primate lentiviral accessory genes, i.e. nef and vpu, that antagonize host restriction factors
in a species-specific manner also have activities that seem largely independent of the host
species. It thus seems beneficial for primate lentiviruses to target antiviral factors by proteins
that exhibit functional plasticity. A viral gene encoding a product that becomes entirely non-
functional, and cannot readily adapt to a new host environment after cross-species transmission
is likely prone to elimination by the rapid accumulation of mutations. However, genes encoding
proteins capable of performing multiple functions, including at least one that is not species-
specific, will be maintained and may evolve to regain lost activities, sometimes perhaps even
at the cost of losing another activity. The acquisition of anti-tetherin activity by HIV-1 group
M Vpus, and the loss of anti-CD4 activity by HIV-1 group N Vpus may represent examples
of this.
Tetherin May Represent a Barrier for Cross-specicies Transmissions of SIVs to Humans
While the specificity of the Vpu/tetherin interaction resembles that of other anti-retroviral host
restriction factors and their viral antagonist, such as APOBEC3G and Vif (Gaddis et al.,
2004; Sawyer et al., 2004; Schröfelbauer et al., 2004; Zennou and Bieniasz, 2006), there is one
important difference: other restriction factors such as APOBEC3G and TRIM5α are unlikely
to pose a barrier to cross-species transmission of SIVcpz from chimpanzees to humans.
Specifically, the SIVcpz Vif protein is fully capable of eliminating the antiviral activity of
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human APOBEC3G (Gaddis et al., 2004), while the SIVcpz capsid is not susceptible to
restriction by human TRIM5α (Kratovac et al., 2008). Altogether, these previous studies
suggested that SIVcpz did not have to overcome a major species barrier to transmission to
humans because chimpanzees and humans are genetically closely related. Our finding that
SIVcpz Vpus and Nefs were generally poorly active in antagonizing HU tetherin challenges
this dogma and strongly suggests that tetherin constitutes a significant barrier to transmission.
Our data also provide compelling evidence that host-specific adapation allowed pandemic
HIV-1 M strains to overcome this restriction because its Vpu protein gained anti-tetherin
activity while maintaining its ability to degrade CD4. In the absence of such adaptation, SIVcpz
strains that have crossed the species barrier may not spread efficiently. This may explain why
just one of three independent chimpanzee-to-human transmissions of SIVcpz has led to a
pandemic. Our finding that Vpus from all group M clades are capable of antagonizing tetherin
suggests that this function was acquired early in the evolution of HIV-1 group M. Moreover,
the ten vpu alleles from transmitted/founder HIV-1 strains that are responsible for productive
infection in humans all antagonized tetherin. In contrast, Vpu proteins of HIV-1 group O are
poor tetherin antagonists and this is also true for this group’s Nef proteins. It will thus be
interesting to investigate whether HIV-1 O has evolved other mechanisms to counteract this
restriction factor (similar to HIV-2). Finally, Vpu alleles from some HIV-1 group N strains
exhibit Vpu mediated anti-tetherin activity (Figure 3C) but appear to have lost the CD4
degradation function (Figure 2B). Thus, imperfect adaptation of HIV-1 O and N to the human
host may explain why they have spread substantially less efficiently in the human population
than HIV-1 M.
Conclusions
In summary, our data suggest that evolutionary switches between Nef- and Vpu-mediated
tetherin antagonism facilitated the cross-species transmission that ultimately led to the
emergence of pandemic HIV-1 strains. The differences in HIV-1 group M, O and N Vpu
function identified here should provide important insights into the role of Vpu and tetherin
antagonism in virus transmission and pathogenesis. It has been previously shown that the
primate lentiviral lineage that gave rise to HIV-1 lost its ability to suppress T-cell activation
(Schindler et al., 2006). Thus, HIV-1 may need a particularly effective tetherin antagonist for
effective virus release because it induces higher levels of inflammation (and thus possibly
tetherin) than non-pathogenic natural SIV infections (Kirchhoff, 2009). Finally, the present
report shows that - with respect to Nef and Vpu function - SIVgsn, SIVmon and SIVmus more
closely resemble HIV-1 M, than SIVcpz or other known SIVs. Thus, studies of these natural
SIV infections may provide relevant insights into the pathogenesis of AIDS in humans.
MATERIALS AND METHODS
Vpu, Nef and Tetherin Expression Vectors
Constructs expressing N-terminally HA-tagged tetherins have been described previously (Neil
et al., 2008; McNatt et al., 2009). Vpu alleles from the different subtypes of HIV-1 M and some
tetherin variants were chemically synthesized (GenScript) (Table S1, Table S2). Cloning of
vpu, nef and tetherin alleles into the bi-cistronic CMV-based pCGCG expression vector
coexpressing the green fluorescent protein (GFP) was essentially performed as described
previously (Greenberg et al., 1998; Schindler et al., 2003). See the Supplemental Experimental
Procedures for details.
Proviral HIV-1 Constructs
Generation of HIV-1 (NL4-3-based) proviral constructs containing a deletion of nucleotides 3
to 120 of the vpu coding frame (ΔVpu) or functional nef genes followed by an IRES and the
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eGFP gene (Nef/eGFP) has been described previously (Rucker et al., 2004; Schindler et al.,
2003; Schindler et al., 2006). To generate vpu-defective derivatives of the HIV-1 Nef/eGFP
constructs (ΔVpu/Nef/eGFP), restriction fragments encompassing the nef-IRES-eGFP region
were cloned into the ΔVpu proviral HIV-1 construct using the unique StuI and NotI restriction
sites in the env gene and the flanking vector sequence, respectively. Proviral HIV-1 NL4-3
vectors expressing various vpu alleles independently of overlapping env gene sequences were
generated using splice-overlap extension PCR and standard cloning techniques as outlined in
the Supplemental Experimental Procedures. All PCR-derived inserts were sequenced to
confirm their accuracy.
Amplification of HIV-1 N and O nef and vpu alleles
Blood samples were obtained from HIV-1 infected people living in Cameroon. Genomic DNA
was extracted from buffy-coat and fragments spanning the nef and vpu genes were amplified
by nested or semi-nested PCR. For details, see the Supplemental Experimental Procedures.
Cell culture and transfections
Cells were cultured and transfected as described in the Supplemental Experimental Procedures.
CD4 cell surface expression
To determine the effect of Vpu on CD4 cell surface expression, 293T cells were transfected
by the calcium phosphate method in triplicate with 1 µg of a CD4 expression vector and 5 µg
of pCGCG GFP/Vpu or GFP/Vpu-AU1 constructs expressing GFP alone or together with
untagged or tagged Vpus. Two days post-transfection CD4 expression was examined by FACS
analysis as described previously (Schindler et al., 2003). See Supplemental Experimental
Procedures for details.
Virus yield and infectivity assays
Virus yield and infectivity assay were conducted in principle as described (Munch et al., 2007;
Neil et al., 2008; McNatt et al., 2009; Zhang et al., 2009). For details, see the Supplemental
Experimental Procedures.
Western blot analysis
The effects of Vpu and Nef on viral particle release were monitored as described previously
(Neil et al., 2008; NcNatt et al., 2009; Zhang et al., 2009). Expression of Vpu and tetherin, as
well as of viral genes by proviral NL4-3 UIE constructs was examined as described in the
Supplemental Experimental Procedures.
Sequence analyses and accession numbers
Tetherin and Vpu amino acid sequences were aligned using Multalign and ClustalW2,
respectively, followed by some manual editing. Newly derived vpu, nef and tetherin sequences
will be submitted to the GenBank sequence database and accession numbers will be provided
upon acceptance of the manuscript.
Statistical analysis
All statistical calculations were performed with a two-tailed unpaired Students-t-test using
Graph Pad Prism Version 5.0. P values <0.05 were considered significant. Correlations were
calculated with the linear regression module.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Alignment of HIV-1 and SIV Vpu amino acid sequences. The NL4-3 Vpu sequence is shown
on top for comparison. The hydrophobic transmembrane (TM) domain, the central charged
region, the position of two serine phosphorylation sites and a β-turn motif in the NL4-3 Vpu
protein are indicated. Dashes indicate gaps introduced to optimize the alignment. Acidic
residues (E, D) are highlighted in green, basic residues (K, R) in blue, hydrophobic residues
(I, V, L) in orange and residues that can potentially be phosphorylated (S, T, Y) in red.
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Figure 2. Suppression of CD4 surface expression by HIV-1 and SIV Vpus
(A) FACS analysis of 293T cells cotransfected with a CD4 expression vector and pCGCG
plasmids expressing GFP alone (GFP only) or together with the indicated vpu alleles.
Constructs expressing the NL4-3 Nef and the mutant NL4-3 S52A Vpu were used as positive
and negative controls, respectively.
(B) Reduction of Vpu-mediated CD4 expression in 293T cells. Shown is the reduction in the
levels of CD4 cell surface expression relative to those measured in cells transfected with the
GFP only control vector. The range of GFP expression used for the calculation is indicated in
panel A. Each symbol represents one of the 57 vpu alleles examined (Table S1) or the indicated
controls. Shown are average values derived from three experiments. The GFP control is color
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coded green, vpu alleles derived from SIVgsn, SIVmon and SIVmus grey, SIVcpz and SIVgor
magenta, HIV-1 M red, O blue and N orange.
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Figure 3. Tetherin antagonism by primate lentiviral Vpu proteins
(A) Alignment of tetherin amino acid sequences from humans (HU), chimpanzees (CPZ),
gorillas (GOR), Greater spot-nosed monkeys (GSN), Mustached monkeys (MUS), Mona
monkeys (MON-L, C. mona lowei), African green monkeys (AGM) and rhesus macaques
(RM). Amino acid identity is indicated by dots and gaps by dashes. Differences between HU
and CPZ tetherins are highlighted by yellow boxes and variations in the TM domain of monkey
tetherins by grey boxes. Known domains, the serine GPI anchor site (red box) and two potential
glycosylation sites (underlined), are indicated.
(B) Effect of various Vpus on infectious virus release in the presence of the indicated tetherin
molecules. 293T cells were cotransfected with HIV-1 ΔVpu NL4-3 (2 µg), pCGCG vectors
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expressing GFP alone or together with Vpu (500 ng), and tetherin expression constructs (50
ng). Viral supernatants were obtained 2 days later and used to measure the quantity of infectious
HIV-1 in the culture supernatants by infecting TZM-bl indicator cells. Shown are average
values ±SD (n=3) of infectious virion yield relative to those obtained in the absence of tetherin
expression vector (100%). The results were confirmed in at least two independent experiments.
(C) Infectious virus release from 293T cells expressing vpu alleles from the indicated primate
lentiviruses and tetherins from their respective host species. The experiments were performed
as described in panel B. Each symbol represents the average infectious virus release (n=3)
obtained in the presence of one of the 55 individual vpu alleles analyzed.
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Figure 4. Tetherin antagonism by primate lentiviral Nef proteins
(A) Infectious virus and p24 antigen yield from 293T cells cotransfected with the proviral
HIV-1 NL4-3 ΔVpu ΔNef construct (Rucker et al., 2004) containing disrupted vpu and nef
genes (2 µg), pCGCG vectors expressing the indicated nef alleles or the NL4-3 Vpu protein
(500 ng), in combination with plasmids expressing the HU, CPZ or GOR tetherins or a Hu
tetherin variant in which the N-terminal deletion was restored (HU-INS) (50 ng). The upper
panel shows the average values derived from triplicate infections of TZM-bl indicator cells
and the lower panel the quantity of p24 antigen in the culture supernatant. All values are shown
relative to those obtained in the absence of tetherin expression vector (100%) the levels of
cellular p24 expression did not differ significantly (data not shown).
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(B) Western blot analysis of cell and virion lysates following cotransfection of 293T cells with
vpu-defective proviral Vpu/Nef/GFP HIV-1 NL4-3 constructs expressing the indicated nef
alleles and 50 ng of empty vector (control) or HU or CPZ tetherin-HA expression plasmids.
Cell and virion lysates were probed with an anti HIV-1 capsid p24 monoclonal antibody. A
proviral HIV-1 NL4-3 construct containing defects in both vpu and nef genes was used in the
“none” and “control” lanes. Sup., cell culture supernatant.
(C) Infectious virus release from 293T cells expressing nef alleles from the indicated primate
lentiviruses and tetherins from their respective host species. The experiments were performed
as described in panel A. The symbols represent the average infectious virus release (n=3)
obtained in the presence of one of the 25 nef alleles analyzed. ***, p<0.0001.
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Figure 5. Titration of anti-tetherin antagonism
(A, B) Virus release from 293T cells following transfection with 2 µg of a ΔVpu/ Nef proviral
NL4-3 construct, 500 ng of SIV (A) or HIV-1 (B) Vpu (color coded red) or Nef (color coded
blue) expression constructs and varying amounts of plasmids expressing the tetherin molecules
from the respective host species. Infectious virus was determined by infection of TZM-bl
indicator cells (upper panels) and p24 ELISA (lower panels) is shown as a percentage of that
detected in the absence of tetherin (100%). All infections shown in panels A–C were performed
in triplicate and the results were confirmed in an independent experiment.
(C) HIV-1 O Nefs are inactive against HU tetherin. The assays were performed as described
in panels A and B. Shown are average values obtained using seven group O (HJ428, HJ036,
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HJ736, HJ100, HJ256, 13127 and 8161) and three SIVcpz Ptt (Gab1, MT145, MB897) nef
alleles.
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Figure 6. Hypothetical model of tetherin driven Vpu and Nef evolution
(A) Schematic of the acquisition of vpu and the subsequent transfer of vpu and nef genes from
monkeys to chimpanzees and to humans by zoonotic primate lentiviral transmissions. The
events that led to the emergence of pandemic HIV-1 group M are indicated by thick lines. Nef-
mediated tetherin antagonism is indicated by blue and Vpu-mediated tetherin antagonism by
red lines, respectively. The lower part summarized the results of the present study and previous
data on Nef function. Note that the upper part is hypothetical as the ancient vpu and nef genes
are not available for analysis.
(B) Tetherin-driven evolution of Vpu and Nef function. Nef is present in all primate lentiviruses
and interacts with the cytoplasmic tails (CTs) of tetherin and CD4. Vpu was initially acquired
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by a precursor of SIVgsn/mus/mon and also targets the CT of CD4 but antagonizes tetherin by
interacting with its transmembrane (TM) domain. The vpu-containing precursor of SIVgsn/
mon/mus (upper left) recombined with that of SIVrcm (lower left) in chimpanzees and the
resulting recombinant virus, i.e. SIVcpz, was subsequently transmitted to humans. Since Nef
and Vpu inhibit tetherin in a species-specific manner they were most likely initially poorly
active against CPZ tetherin. Subsequently, Nef evolved to become an effective tetherin
antagonist in chimpanzees (middle). Upon cross-species transmission of SIVcpz to humans,
however, this Nef function was most likely disrupted by a unique deletion in the CT of the
human restriction factor. Subsequently, Vpu evolved to counteract HU tetherin during the
emergence of pandemic HIV-1 M strains (upper right). In comparison, HIV-1 O Vpus remained
poor tetherin antagonists (middle right) and those from HIV-1 N lost the CD4 degradation
activity (lower right). Matching colors indicate that Vpu and Nef recognize their TM and CT
interaction sites in the tetherin molecules. Broken grey arrows indicate disrupted or impaired
activities.
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